国色A片V一区二区三区下,把女人弄爽特黄a大片,扒开粉嫩小泬直接进视频,久久久久 亚洲 无码 AV 专区

您好，歡迎光臨上海雅吉生物商城！
工作時(shí)間：9:00-18:00
全國(guó)服務(wù)熱線：021-34661276

Purified anti-mouse CD274 (B7-H1, PD-L1) Antibody

訂購(gòu)數(shù)量：
規(guī)格
價(jià)格庫(kù)存
訂購(gòu)熱線：021-34661276
我要詢價(jià)
  • 商品詳情
  • 售后服務(wù)
  • 相關(guān)文獻(xiàn)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 ?g per million cells in 100 ?L?volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  3. Dieterich LC, et al. 2017. Front Immunol. 0.379166667. PubMed
  4. Iwai T, et al. 2021. Mol Cancer Ther. 20:2519. PubMed
  5. Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed
  6. Herold M, et al. 2015. J Immunol. 195: 3584 - 3595. PubMed
  7. Wang G, et al. 2020. Nat Commun. 11:1395. PubMed
  8. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  9. Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed
  10. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  11. Lei G, et al. 2015. Infect Immun . 83:572. PubMed
  12. Singh M, et al. 2017. Nat Commun. 8:1447. PubMed
  13. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  14. Meng Q, et al. 2006. Invest Ophthalmol Vis Sci. 47:4444. PubMed
  15. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  16. Kong F, et al. 2021. Front Immunol. 12:670646. PubMed
  17. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  18. Yahata T, et al. 2019. Cancer Sci. 110:1279. PubMed
  19. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  20. Speranza MC, et al. 2018. Neuro Oncol. 20:225. PubMed
  21. Sano Y, et al. 2021. Mol Cancer Res. 19:507. PubMed
  22. Zhao T, et al. 2022. JCI Insight. 7:. PubMed
  23. Scarlett U, et al. 2012. J Exp Med. 209:425. PubMed
  24. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
  25. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  26. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  27. Lin A, et al. 2022. Bioeng Transl Med. 7:e10314. PubMed
  28. Iida Y, et al. 2020. J Immunother Cancer. 8:. PubMed
  29. Bassi &, et al. 2012. Diabetes. 61:2534. PubMed
  30. Li Z, et al. 2022. Transl Cancer Res. 11:3698. PubMed
  31. Hirose T, et al. 2017. PLoS One. 12(6):e0178765. PubMed
  32. Knier B, et al. 2018. Nat Immunol. 1.722916667. PubMed
  33. Giles DA, et al. 2018. J Clin Invest. 128:5322. PubMed
  34. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
RRID
AB_961226 (BioLegend Cat. No. 124301) AB_961228 (BioLegend Cat. No. 124302)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
我要詢價(jià)
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯(lián)系方式不會(huì)被公開)
*內(nèi)容：


微信客服
掃一掃立即咨詢


微信客服
掃一掃立即咨詢

銷售電話：

021-34661275

021-34661276

15301693058